Curative Biotechnology's rare-disease focus predates its current name and spans more than one therapeutic area. It formerly operated as Connectyx Technologies Holdings Group, a development-stage biomedical company. The company identifies, acquires, and develops disease-modifying drug candidates, maintaining programs in degenerative eye disease, infectious disease, and neuro-oncology.
Its lead candidate is a topical eye formulation based on metformin for intermediate- and late-stage age-related macular degeneration, developed under a worldwide exclusive license from the National Eye Institute. Allowed patent claims cover administering metformin topically to the eye for retinal degeneration, including age-related macular degeneration and Stargardt's disease.
Metformin Reformulation is a licensed reformulation of metformin for retinal degeneration, first targeting intermediate dry AMD and geographic atrophy.